Study of a new drug for advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental drug called KM602 for people with advanced solid tumors that have stopped responding to standard treatments, particularly melanoma and non-small cell lung cancer. It aims to see if the drug is safe and effective in shrinking or controlling tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid tumor cancer, especially melanoma or non-small cell lung cancer, that has spread or can't be removed.
- You have at least one tumor that can be measured on scans.
- You are able to perform most daily activities (ECOG 0 or 1).
- You have a life expectancy of at least 12 weeks.
- You have adequate organ function (blood, kidney, liver).
- You have not been treated with certain immunotherapy (CTLA-4 inhibitors like ipilimumab) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called KM257 for people with advanced solid tumors that have a high level of a protein called HER2. The drug is given as an infusion and is designed to target cancer cells with this protein, potentially slowing or stopping tumor growth.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called KH801, which may help the immune system fight cancer. It's for people whose cancer has spread or can't be removed and who have already tried other treatments without success. The goal is to see if the drug is safe and if it helps slow down the cancer.
This study tests an investigational drug (KM501) for advanced solid tumors that have HER2 changes. It aims to see if the drug can shrink tumors or slow their growth, and whether it is safe for patients who have run out of standard options.
This trial tests a new drug called JSKN027 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this drug is safe and if it can shrink tumors or slow their growth.
This study tests an investigational cell therapy (GK01) for people with advanced solid tumors that have grown despite standard treatment or have no standard treatment option. It may help shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.